| dc.contributor.author |
Murugesan, Sankaranarayanan |
|
| dc.date.accessioned |
2025-03-10T09:20:44Z |
|
| dc.date.available |
2025-03-10T09:20:44Z |
|
| dc.date.issued |
2025-02 |
|
| dc.identifier.uri |
https://www.benthamdirect.com/content/journals/mc/10.2174/0115734064301748240821081206 |
|
| dc.identifier.uri |
http://dspace.bits-pilani.ac.in:8080/jspui/handle/123456789/18240 |
|
| dc.description.abstract |
It is noteworthy that a wide array of plants and nutraceuticals are effectively utilized in the treatment of various cancers, demonstrating potent effects on different cancer targets with fewer side effects. Notably, estrogen alpha has been identified as a crucial factor in breast cancer cell proliferation. Agents that can antagonize its action hold promise as potential drug leads for the treatment of breast cancer. |
en_US |
| dc.language.iso |
en |
en_US |
| dc.publisher |
Bentham Science |
en_US |
| dc.subject |
Pharmacy |
en_US |
| dc.subject |
ADME(T) |
en_US |
| dc.subject |
Breast cancer |
en_US |
| dc.subject |
Drug development |
en_US |
| dc.subject |
MD analysis |
en_US |
| dc.subject |
Molecular docking |
en_US |
| dc.subject |
Nutraceuticals |
en_US |
| dc.title |
In silico studies of phytoconstituents to identify potential inhibitors for erα protein of breast cancer |
en_US |
| dc.type |
Article |
en_US |